drugset / Trial / NCT06987318
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Phase 1
Not yet recruiting
40 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Monogram Biosciences · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Timeline
- Start
- 2026-12-01
- Primary completion
- 2027-08-29
- Completion
- 2028-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PGT121.414.LS | Monoclonal antibody | — | Intravenous |
| Subject | VRC07-523LS | Monoclonal antibody | — | Intravenous |